Hyperammonemia in ICU patients: A frequent finding associated with high mortality  by Prado, Fabrizio A. et al.
Letters to the Editor
1216
Open access undHyperammonemia in ICU patients: A frequent ﬁnding
associated with high mortalityTo the Editor:
Hyperammonemia usually develops because of acute liver failure
(ALF) or chronic liver disease (CLD), but it may occur in the
absence of hepatic disease (non-hepatic hyperammonemia,
NHH). Hyperammonemia may induce encephalopathy, which
can range from mild cognitive disturbances to coma, cerebral
edema, brain stem herniation, and death [1]. Critically ill patients
constitute a population where several risk factors for NHH are
present [2,3]. Despite this fact, studies on incidence and possible
etiologies of this disorder in this population are lacking.
We conducted a prospective observational study in a
medical–surgical intensive care unit (ICU) and in a burn ICU of
the Londrina University Hospital (Londrina, PR, Brazil) between
March 2012 and September 2012. All adult patients aged
P18 years admitted to these ICUs were included (n = 258).
Exclusion criteria were ALF, CLD, death within the ﬁrst 24 h of
admission, patients discharged from the ICUs within 48 h of
elective surgery, or lack of signed informed consent. The local
ethics committee approved the study and all research subjects
(or their surrogates) provided written informed consent before
being included in the study.
Arterial ammonia levels were collected at admission and on
the third, seventh, fourteenth, twenty-ﬁrst, and twenty-eighth
days after admission and were analyzed together with severity
scores, admission diagnostics, and predisposing factors for
NHH. Blood samples were stored in ice, centrifuged within
30 min, and analyzed by an enzymatic method with glutamate
dehydrogenase as the reagent [4]. Patients were classed as hyper-
ammonemic if their ammonia levels were above 35 lmol/L at any
time. NHH was further classiﬁed as mild (36–99 lmol/L) and sev-
ere (P100 lmol/L) [5].
Demographics, admission diagnostics (classiﬁed as sepsis,
multiple trauma, burn injury, post-operative state, lymphoma/
leukemia/multiple myeloma, and other), and APACHE II [6] score
were obtained at the ICU admission. The SOFA [7] score was cal-
culated at admission and every subsequent day. The conditions
considered risk factors for NHH and investigated on a daily basis
are presented in Table 1.
After exclusions (n = 158), one hundred patients remained in
the study, 22 of them with burn injuries. Seventy-three patients
presented hyperammonemia, which was classiﬁed as mild in 60
cases and severe in 13 cases. Hyperammonemia was observed in
40% of patients in the ﬁrst day of ICU stay and by the 3rd day of
ICU stay, cumulative incidence of NHH reached 60%. Ammonia
levels ranged from 36 to 1616 lmol/L (median 57 lmol/L). Only
thirteen out of the 73 NHH patients presented risk factors for
the condition (2 valproic acid and 2 carbamazepine use, 3 gas-
trointestinal hemorrhage, 1 with UTI due to urease-splitting
organisms, 1 with urinary diversion, and 4 with convulsions).
Cox regression analysis using patients’ characteristics at
admission did not indicate any statistically signiﬁcant association
among NHH, admission diagnostics, age, and severity scores.Journal of Hepatology 20
er CC BY-NC-ND license.Associations of NHH with possible risk factors and other
conditions present on the day of hyperammonemia appearance
are presented in Table 1. NHH occurrence was statistically
associated with the SOFA score and prolonged fasting.
Mortality rates were statistically signiﬁcant (v2 test; p <0.01
for comparison between all groups) between patients with severe
(10/13, 76.92%) and moderate hyperammonemia (25/60, 41.67%)
and between this last group and patients without hyperammone-
mia (3/27, 11.11%).
Urea cycle disorders rarely cause NHH in adults and usually
present with much higher ammonia levels (only one patient in
our series had very high ammonia levels). Patients with ALF
and CLD were excluded from this study and serum bilirubin
levels were not associated with the occurrence of hyperam-
monemia; however, we could not exclude speciﬁc harm to
hepatic ammonia clearance systems since aminotransferases
were only dosed if indicated by the ICU staff and did not ﬁgure
in the statistical analysis. When liver capacity is surpassed due
to increased ammonia production and/or reduced ammonia
degradation, kidneys, muscles and central nervous system (in
a much smaller scale), increase their participation in ammonia
detoxiﬁcation [8]. In our study, the estimated glomerular ﬁltra-
tion rate was similar in patients with and without NHH but
urinary ammonia excretion was not studied. Regarding muscle
tissue, the positive association between NHH and prolonged
fasting seen in this study could be linked to fasting-induced
muscle protein breakdown with the utilization of amino acids
for gluconeogenesis [9], resulting in increased substrate for
ammonia generation. Another possible explanation is provided
by Görg et al., which demonstrated, in a murine model of
sepsis, that the enzyme glutamine synthetase is both down-
regulated and inactivated due to tyrosine nitration induced
by LPS infusion [10].
In conclusion, the present study demonstrated, for the ﬁrst
time, the incidence of NHH in ICU patients. It occurred early and
frequently, and it was associated with increased mortality, high
SOFA scores, and fasting. Risk factors commonly ascribed to the
condition were uncommon, and statistical analysis did not ﬁnd
a correlation between them and NHH appearance. The detailed
pathogenesis of NHH in critically ill patients and whether NHH
contributes to patient mortality or it is merely an epiphenomenon
of severe illness arematters for further research. Nevertheless, the
present ﬁndings should encourage the investigation for NHH in
critically ill patients, as it is a potentially life-threatening, treat-
able disorder.
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Table 1. Risk of hyperammonemia development based on patient characteristics on the day of its appearance.
Univariate Cox regression analysis. Frequencies and percentages for categorical variables, medians and interquartile range for continuous variables. In ﬁrst column, in
parenthesis, after SOFA, INR, urea, total calories, and total nitrogen, the number of patients from the groups with and without NHH, respectively, that had the parameter
available for analysis on the day of onset of hyperammonemia.
SOFA, Sequential Organ Failure Assessment; INR, international normalized ratio; eGFR, glomerular ﬁltration rate estimated by the 4 variable MDRD equation; GI,
gastrointestinal.
aPatients only receiving oral diet were not included.
bRecorded as the sum of either enteral or parenteral nutrition.
cFasting for P24 h.
dIleal conduit in the only patient.
eUTI by urea splitting organisms.
⁄p <0.05.
NHH HR (95% CI)
Yes No
73 27
51 (24.7-66.7) 63 (42-74) 0.994 (0.984-1.005)
48 (65.8%) 13 (48.1%) 1.413 (0.864-2.312)
6 (3-10.7) 3 (1-5) 1.082 (1.026-1.141)*
7/67 (10.4%) 0/26 (0%) 2.038 (0.922-4.507)
1.28 (1.19-1.69) 1.16 (0.98-1.46) 1.445 (0.693-3.015)
29/73 (39.7%) 12/26 (46.2%) 0.837 (0.519-1.352)
43 (26.2-93.7) 57 (28-88.5) 0.997 (0.991-1.003)
28/73 (38.4%) 7/27 (25.9%) 1.297 (0.807-2.083)
1/73 (1.4%) 0/27 (0%) 2.310 (0.319-16.722)
0/73 (0%) 3/27 (11.1%) 0.047 (0.000-15.064)
774 (0-1512) 1023 (496-1480) 1.000 (0.099-1.000)*
4,95 (0-9,7) 6.5 (3.15-9.42) 0.957 (0.915-1.001)
11/73 (15.1%) 0/27 (0%) 1.192 (0.626-2.272)
19/73 (26.0%) 1/27 (3.7%) 2.308 (1.332-3.999)*
1/73 (1.4%) 0/27 (0%) 2.310 (1.332-3.999)
1/73 (1.4%) 0/27 (0%) 2.310 (0.319-16.722)
0/73 (0%) 0/27 (0%)





Total bilirubin >2.0 mg/dl
INR (40/12)





Total caloriesa,b Cal/d (62/12)







Chemotherapy 0/73 (0%) 0/27 (0%)
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